NCT07125209Recruiting
Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 18 (estimated)
- First submitted
- 7 Aug 2025
- Start date
- 28 Apr 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Ovarian cancer
- NCT number
- NCT07125209
What you commit to
- Study type: Observational
- Planned participants: 18
- From 28 Apr 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of diagnosed cognitive impairment, including dementia
- History of traumatic brain injury
- Known hearing or visual impairment not corrected with hearing devices and glasses/contacts
- Upper extremity motor impairment that would impact ability to perform the Trail Making Test
Other
- English is not their primary language
- Baseline Mini Mental State Exam (MMSE) score less than 18
Who the study is looking for
- Age 18 or older
- Pathological diagnosis of suspected epithelial ovarian cancer; of note, patients with suspected epithelial ovarian cancer who are pending a pathological diagnosis/biopsy may be enrolled onto the study ahead of their biopsy. If the biopsy result is later inconsistent with epithelial ovarian cancer, they will be removed from the study and replaced
- Planned to received neoadjuvant chemotherapy with carboplatin and paclitaxel; alternatives to these agents including abraxane, docetaxel, cisplatin may be used if patients have a chemotherapy reaction or otherwise cannot receive carboplatin and paclitaxel per usual standard of care
- Patients may be receiving bevacizumab and may receive PARP inhibitors as a maintenance treatment; those receiving any other targeted therapy will be excluded
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UW Carbone Cancer Center Coordinator of this site? Confirm its status | Madison | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.